glp 1 clinical trials recruiting GLP-1a: Going beyond Traditional Use 3 Takeaways from the Landmark

When compared to those taking a placebo and with all participants eating a standardized breakfast, people taking semaglutide ate 24% less overall and approximately 35% less during their lunch and evening meals

Only 34% of GLP-1 patients on DPP-4 inhibitors, a class of oral diabetic medications also known as gliptins, were still taking DPP-4 inhibitors 52 weeks after starting GLP-1 therapy according to Earnest pharmacy claims data

In this context, GLP-1based pharmacotherapies have emerged as a valuable adjunct to lifestyle modification, with growing evidence supporting their role in improving weight-related and cardiometabolic outcomesThis review has examined the mechanisms of action, clinical efficacy, safety considerations, and future directions of GLP-1 single, dual, and triple agonists, with a focus on their potential relevance to adolescent obesity management

The median follow-up period for the entire cohort was 2.3 years